Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation: should we test for it, and does it matter?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2013

Roberts Patrick J, Stinchcombe Thomas E

Abstract excerpt

Lung cancer is the leading cause of cancer mortality in the United States and worldwide. Previously, lung cancer was simplistically divided into non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, in the last decade, we have gone from a simplistic binary system of classifying lung cancer to defining NSCLC on the basis of molecular subsets. KRAS mutations represent the most common molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Techniques

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 23401440
DOI: 10.1200/JCO.2012.43.0454

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation: should we test for it, and does it matter?PMID 23401440Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.Semantic proximity Read ↗

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Semantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.